新诊断全身型肌无力的亚组分层与结局
该回顾性研究纳入奥地利两家三级中心2000年后起病的199例全身型肌无力患者,按早发/晚发AChR抗体阳性、MuSK抗体阳性、血清阴性及胸腺瘤分层,评估症状严重度、治疗方案及危及生命事件至10年。结果显示63%患者最终达到微小表现状态或更好并维持>1年,MuSK-MG结局优于既往报道,诊断亚组是结局最强预测因素。
要点
- 63%全身型肌无力患者最终达到微小表现状态或更好并维持>1年
- 诊断亚组是长期结局最强预测因素,MuSK-MG结局优于既往报道
核心结论
- 诊断亚组和起病2年内治疗应答有助于预测全身型肌无力的长期结局。
研究设计与样本
- 回顾性分析199例2000年后起病的全身型肌无力患者,来自奥地利两家三级转诊中心。
主要发现
- 125例(63%)最终达到微小表现状态或更好并维持>1年。
- 19%患者起病2年后仍持续有症状,后续更治疗抵抗。
- MuSK-MG患者结局远优于既往报道。
关键数值与推荐
- 按早发/晚发AChR抗体阳性、MuSK抗体阳性、血清阴性及胸腺瘤(不论抗体状态)分层。
- 每年评估症状严重度、治疗方案及危及生命事件,至多10年。
临床怎么用
- 对全身型肌无力应按诊断亚组分层管理,并关注起病2年内治疗应答以预判长期结局。
局限性
- 回顾性设计,仅两家奥地利三级中心,样本代表性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To describe disease outcomes of myasthenia gravis (MG) subgroups and which factors influence outcomes by reviewing individual patient records of a representative cohort. METHODS: We performed a retrospective analysis of 199 patients with generalized MG and disease onset after the year 2000 who were treated at 2 tertiary referral centers in Austria. We stratified patients as early- and late-onset acetylcholine receptor antibody-positive, muscle-specific tyrosine kinase (MuSK) antibody-positive, and seronegative patients and patients with thymoma regardless of antibody status. We evaluated patients' symptom severity and treatment regimens and the occurrence of life-threatening events at yearly time points for up to 10 years. RESULTS: Minimal manifestation status or better was eventually achieved and sustained for >1 year by 125 (63%) patients. Forty percent (66 of 165 patients) showed an early response to treatment, which predicted a benign disease course later on. In contrast, 19% of patients, who remained symptomatic for 2 years after disease onset despite immunosuppressive therapy, were more treatment resistant in the following years. The strongest predictor of outcome was the diagnostic subgroup. Patients with MuSK-MG had a much better outcome than previously reported. CONCLUSION: Our data give an update on the disease course of generalized MG in the new century. Diagnostic subgroups and response to treatment within the first 2 years help to predict the long term outcome.
引用
- Tomschik M, Hilger E, Rath J, et al. Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology. 2020. PMID: 32641537. doi:10.1212/WNL.0000000000010209
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。